Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
63
SYRE Quote, Financials, Valuation and Earnings
Last price:
$47.58
Seasonality move
:
-1.09%
Day range:
$46.27 - $48.40
52-week range:
$10.91 - $51.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
701.12x
P/B ratio:
6.50x
Volume:
438K
Avg. volume:
845.9K
1-year change:
207.17%
Market cap:
$3.6B
Revenue:
--
EPS (TTM):
-$2.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$0.66 | 315.28% | -8.42% | $60.79 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$283.1M | $0.07 | 16.03% | -30.17% | $31.85 |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$13.9M | -$1.78 | 56.38% | -15.51% | $43.13 |
|
SVRA
Savara, Inc.
|
-- | -$0.14 | -- | -12.28% | $10.81 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$240.6M | -$0.44 | 2.62% | -77.49% | $30.76 |
|
TYRA
Tyra Biosciences, Inc.
|
-- | -$0.59 | -- | -24.07% | $51.07 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
$47.58 | $60.79 | $3.6B | -- | $0.00 | 0% | 701.12x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$35.20 | $43.13 | $2.1B | 3.91x | $0.00 | 0% | 38.89x |
|
SVRA
Savara, Inc.
|
$5.56 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
|
TNDM
Tandem Diabetes Care, Inc.
|
$18.61 | $30.76 | $1.3B | -- | $0.00 | 0% | 1.22x |
|
TYRA
Tyra Biosciences, Inc.
|
$39.61 | $51.07 | $2.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -1.674 | -- | 12.89x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.26% | 0.320 | 2.53% | 10.52x |
|
SVRA
Savara, Inc.
|
12.84% | -1.345 | 2.43% | 11.56x |
|
TNDM
Tandem Diabetes Care, Inc.
|
74.33% | 1.046 | 29.94% | 1.92x |
|
TYRA
Tyra Biosciences, Inc.
|
2.19% | -1.931 | 0.41% | 14.15x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$57.2M | -25.86% | -25.86% | -- | -$44.6M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$16.8M | -$121.6M | -29.08% | -30.11% | -608.9% | -$97.3M |
|
SVRA
Savara, Inc.
|
-$40K | -$33.4M | -67.27% | -80.59% | -- | -$25.1M |
|
TNDM
Tandem Diabetes Care, Inc.
|
$167.5M | $8.3M | -32.45% | -121.88% | 2.86% | $3.1M |
|
TYRA
Tyra Biosciences, Inc.
|
-$132K | -$36.5M | -38.98% | -39.76% | -- | -$23.7M |
Spyre Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SYRE or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of 96.33%. Spyre Therapeutics, Inc.'s return on equity of -25.86% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About SYRE or ACAD?
Spyre Therapeutics, Inc. has a consensus price target of $60.79, signalling upside risk potential of 27.76%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Spyre Therapeutics, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Spyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.15 0 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is SYRE or ACAD More Risky?
Spyre Therapeutics, Inc. has a beta of 2.931, which suggesting that the stock is 193.131% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock SYRE or ACAD?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or ACAD?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Spyre Therapeutics, Inc.'s net income of -$51.8M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns SYRE or AGIO?
Agios Pharmaceuticals, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of -541.09%. Spyre Therapeutics, Inc.'s return on equity of -25.86% beat Agios Pharmaceuticals, Inc.'s return on equity of -30.11%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M AGIOAgios Pharmaceuticals, Inc.84.25% -$1.85 $1.2B -
What do Analysts Say About SYRE or AGIO?
Spyre Therapeutics, Inc. has a consensus price target of $60.79, signalling upside risk potential of 27.76%. On the other hand Agios Pharmaceuticals, Inc. has an analysts' consensus of $43.13 which suggests that it could grow by 17.9%. Given that Spyre Therapeutics, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.15 0 0 AGIOAgios Pharmaceuticals, Inc.6 3 0 -
Is SYRE or AGIO More Risky?
Spyre Therapeutics, Inc. has a beta of 2.931, which suggesting that the stock is 193.131% more volatile than S&P 500. In comparison Agios Pharmaceuticals, Inc. has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.263%.
-
Which is a Better Dividend Stock SYRE or AGIO?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Agios Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or AGIO?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than Agios Pharmaceuticals, Inc. quarterly revenues of $20M. Spyre Therapeutics, Inc.'s net income of -$51.8M is higher than Agios Pharmaceuticals, Inc.'s net income of -$108M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Agios Pharmaceuticals, Inc.'s PE ratio is 3.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 38.89x for Agios Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M AGIOAgios Pharmaceuticals, Inc.38.89x 3.91x $20M -$108M
-
Which has Higher Returns SYRE or SVRA?
Savara, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of --. Spyre Therapeutics, Inc.'s return on equity of -25.86% beat Savara, Inc.'s return on equity of -80.59%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M SVRASavara, Inc.-- -$0.13 $233M -
What do Analysts Say About SYRE or SVRA?
Spyre Therapeutics, Inc. has a consensus price target of $60.79, signalling upside risk potential of 27.76%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 94.47%. Given that Savara, Inc. has higher upside potential than Spyre Therapeutics, Inc., analysts believe Savara, Inc. is more attractive than Spyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.15 0 0 SVRASavara, Inc.6 0 0 -
Is SYRE or SVRA More Risky?
Spyre Therapeutics, Inc. has a beta of 2.931, which suggesting that the stock is 193.131% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.
-
Which is a Better Dividend Stock SYRE or SVRA?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or SVRA?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Spyre Therapeutics, Inc.'s net income of -$51.8M is lower than Savara, Inc.'s net income of -$32.2M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M SVRASavara, Inc.-- -- -- -$32.2M
-
Which has Higher Returns SYRE or TNDM?
Tandem Diabetes Care, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of -0.2%. Spyre Therapeutics, Inc.'s return on equity of -25.86% beat Tandem Diabetes Care, Inc.'s return on equity of -121.88%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M TNDMTandem Diabetes Care, Inc.57.67% -$0.01 $604.5M -
What do Analysts Say About SYRE or TNDM?
Spyre Therapeutics, Inc. has a consensus price target of $60.79, signalling upside risk potential of 27.76%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $30.76 which suggests that it could grow by 65.3%. Given that Tandem Diabetes Care, Inc. has higher upside potential than Spyre Therapeutics, Inc., analysts believe Tandem Diabetes Care, Inc. is more attractive than Spyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.15 0 0 TNDMTandem Diabetes Care, Inc.9 11 0 -
Is SYRE or TNDM More Risky?
Spyre Therapeutics, Inc. has a beta of 2.931, which suggesting that the stock is 193.131% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.737, suggesting its more volatile than the S&P 500 by 73.689%.
-
Which is a Better Dividend Stock SYRE or TNDM?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or TNDM?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than Tandem Diabetes Care, Inc. quarterly revenues of $290.4M. Spyre Therapeutics, Inc.'s net income of -$51.8M is lower than Tandem Diabetes Care, Inc.'s net income of -$589K. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 1.22x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M TNDMTandem Diabetes Care, Inc.1.22x -- $290.4M -$589K
-
Which has Higher Returns SYRE or TYRA?
Tyra Biosciences, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of --. Spyre Therapeutics, Inc.'s return on equity of -25.86% beat Tyra Biosciences, Inc.'s return on equity of -39.76%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M TYRATyra Biosciences, Inc.-- -$0.57 $265M -
What do Analysts Say About SYRE or TYRA?
Spyre Therapeutics, Inc. has a consensus price target of $60.79, signalling upside risk potential of 27.76%. On the other hand Tyra Biosciences, Inc. has an analysts' consensus of $51.07 which suggests that it could grow by 28.93%. Given that Tyra Biosciences, Inc. has higher upside potential than Spyre Therapeutics, Inc., analysts believe Tyra Biosciences, Inc. is more attractive than Spyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.15 0 0 TYRATyra Biosciences, Inc.9 0 0 -
Is SYRE or TYRA More Risky?
Spyre Therapeutics, Inc. has a beta of 2.931, which suggesting that the stock is 193.131% more volatile than S&P 500. In comparison Tyra Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SYRE or TYRA?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tyra Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Tyra Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or TYRA?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than Tyra Biosciences, Inc. quarterly revenues of --. Spyre Therapeutics, Inc.'s net income of -$51.8M is lower than Tyra Biosciences, Inc.'s net income of -$33.8M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Tyra Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus -- for Tyra Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M TYRATyra Biosciences, Inc.-- -- -- -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
